UNSPSC 51293609: Pirlindole

This classification denotes a monoamine oxidase inhibitor with the molecular formula C15H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V39YPH45FZ, chemically known as 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino(3,2,1-jk)carbazole but generally known as pirlindole, which bears US NIH Compound Identifier 68802. European Medicines Agency schedules Pirlindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09923MIG.

UNSPSC 51293609 Pirlindole is a Commodity code nominally identifying a single pharmaceutical product, yet recent state and local solicitations tagged under it span a far broader pharmaceutical and health-product procurement landscape: the category captures everything from naloxone and drug deactivation systems to generic multi-source pharmaceuticals and over-the-counter products procured through cooperative purchasing arrangements and direct-to-manufacturer programs. State and local issuing bodies—including county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions—are using this code to solicit pharmaceuticals and related health supplies through a mix of procurement vehicles: individual county IFBs for specialized health products, state-level RFIs for pharmacy benefit program innovation, and multi-state cooperative RFPs for generic pharmaceutical distribution networks.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state interest in reshaping pharmacy benefit procurement outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, requiring vendors to supply through authorized wholesalers and comply with cGMP, DSCSA, and FDA requirements, with contract effectiveness set for July 1, 2026.